Edinburgh Research Explorer

Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium

Citation for published version:
for the ENIGMA Schizophrenia Working Group 2015, 'Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium' Molecular Psychiatry, pp. 1-7., 10.1038/mp.2015.63

Digital Object Identifier (DOI):
10.1038/mp.2015.63

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Molecular Psychiatry

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium

The profile of brain structural abnormalities in schizophrenia is still not fully understood, despite decades of research using brain scans. To validate a prospective meta-analysis approach to analyzing multicenter neuroimaging data, we analyzed brain MRI scans from 2028 schizophrenia patients and 2540 healthy controls, assessed with standardized methods at 15 centers worldwide. We identified subcortical brain volumes that differentiated patients from controls, and ranked them according to their effect sizes. Compared with healthy controls, patients with schizophrenia had smaller hippocampus (Cohen’s $d = -0.46$), amygdala ($d = -0.31$), thalamus ($d = -0.31$), accumbens ($d = -0.25$) and intracranial volumes ($d = -0.12$), as well as larger pallidum ($d = 0.21$) and lateral ventricle volumes ($d = 0.37$). Putamen and pallidum volume augmentations were positively associated with duration of illness and hippocampal deficits scaled with the proportion of unmedicated patients. Worldwide cooperative analyses of brain imaging data support a profile of subcortical abnormalities in schizophrenia, which is consistent with that based on traditional meta-analytic approaches. This first ENIGMA Schizophrenia Working Group study validates that collaborative data analyses can readily be used across brain phenotypes and disorders and encourages analysis and data sharing efforts to further our understanding of severe mental illness.

Molecular Psychiatry advance online publication, 2 June 2015; doi:10.1038/mp.2015.63

1Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA; 2 Imaging Genetics Center, University of Southern California, Los Angeles, CA, USA; 3Department of Psychiatry, Yale University, New Haven, CT, USA; 4Olin Neuropsychiatric Research Center, Institute of Living, Hartford, CT, USA; 5Norwegian Centre for Mental Disorders Research (NORMENT), KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway; 6Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway; 7Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; 8Department of Psychology, University of Oslo, Oslo, Norway; 9Mmil, Department of Radiology, University of California, San Diego, CA, USA; 10Department of Cognitive Science, Neurosciences and Psychiatry, University of California, San Diego, CA, USA; 11Department of Psychiatry, University Medical Center Göttingen, Göttingen, Germany; 12Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry and Psychotherapy, Georg August University, Göttingen, Germany; 13Cognitive Genetics and Therapy Group, School of Psychology, National University of Ireland, Galway, Ireland; 14Neuropsychiatric Genetics research group, Department of Psychiatry and Trinity College Institute of Psychiatry, Trinity College, Dublin, Ireland; 15Clinical Neuroimaging Laboratory, College of Medicine, Nursing and Health Sciences, National University of Ireland, Galway, Ireland; 16Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 17University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 18Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; 19Department of Psychiatry, University of California, San Francisco, CA, USA; 20San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; 21Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA; 22Translational Developmental Neuroscience Section, Department of Child and Adolescent Psychiatry, Technische Universität, Dresden, Germany; 23Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 24MGH/MIT/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA; 25Mind Research Network, Albuquerque, NM, USA; 26Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM, USA; 27Advanced Biomedical Informatics Group, LLC, Iowa City, IA, USA; 28The University of Iowa, Iowa City, IA, USA; 29Minneapolis VA Healthcare System & Department of Psychiatry, University of Minnesota, Twin Cities, MN, USA; 30Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands; 31Center for Neurobehavioral Genetics, University of California, Los Angeles, CA, USA; 32Division of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria-IDIVAL, Santander, Spain; 33CIBERSAM, Centro Investigación Biomédica en Red de Salud Mental, Madrid, Spain; 34Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Northwestern University, Evanston, IL, USA; 35Department of Radiology, Northwestern University Feinberg School of Medicine, Northwestern University, Evanston, IL, USA; 36Division of Psychiatry, University of Edinburgh Medical School, Edinburgh, UK; 37Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan and 38Departments of Psychology and Neuroscience, Georgia State University, Atlanta, GA, USA. Correspondence: Dr JA Turner, Departments of Psychology and Neuroscience, Georgia State University, 758 Urban Life, Atlanta, GA 30302-5010, USA. E-mail: jturner63@gsu.edu

39Joint first-authorship.

40For more details regarding the ENIGMA Schizophrenia Working Group, see http://enigma.ini.usc.edu/ongoing/enigma-schizophrenia-working-group.
INTRODUCTION
Achievements based on cooperative analyses of neuroimaging data in severe mental illness trail those in genetics. This manuscript presents a first validation of our approach to collectively analyze neuroimaging data via the ENIGMA Schizophrenia Working Group.

Individuals with schizophrenia show significant brain morphological abnormalities, but there is considerable heterogeneity in the effect sizes and patterns of brain differences across studies. The study of structural brain abnormalities in schizophrenia can help us understand its causes, progression and even treatment effects. Even so, brain differences are influenced by multiple factors—some with opposing effects. Small studies can yield findings that conflict or are not subsequently replicated. Here, we demonstrate a profile of brain abnormalities based on 15 schizophrenia cohorts worldwide, and rank effect size estimates for subcortical and intracranial brain volume differences between individuals with schizophrenia and healthy controls. We also attempt to identify factors that may contribute to effect size heterogeneity across studies.

Despite early suggestion, much collected imaging and associated data does not reside in electronic databases that are easily queried for joint analyses and there are no agreed upon standards for efficient data sharing. Here we report ENIGMA's first analysis of schizophrenia brain morphology using harmonized methods to combine brain volumes across samples. The study provides a proof of concept that prospective analyses of already collected data using similar methods can yield robust findings with sample sizes larger than those achieved via retrospective meta-analyses of published work.

‘Retrospective’ meta-analyses—or traditional meta-analyses that pool statistical findings reported in the literature—are invaluable for summarizing the state of research findings and identifying possible sources of heterogeneity; they also yield effect sizes for power calculations. However, in traditional meta-analyses much of the collected data are not fully explored. For instance, Hajima et al. identified 119 published studies of schizophrenia that reported on whole brain volumes, but only 9 publications that reported on occipital lobe gray matter volumes. For subcortical structures in particular, 87 publications reported hippocampal volumes, but only 13 reported accumbens volumes. Automated image analysis software, and increasingly efficient global collaborations, now allow for prospective analyses of brain scans worldwide using standardized methods. Prospective meta-analyses require the pooling of individual subject data. In contrast, prospective meta-analyses only require the pooling of specific summary statistics—computed at each participating center. This is highly effective even when participants’ consent for individual-level data sharing was not obtained. The power of this approach lies in the consistency of the analyses across data sets rather than the ad-hoc aggregation of statistics from the literature. Large-scale analyses using similar methods across cohorts worldwide can also be applied across traditional diagnostic boundaries to yield robust and consistent anatomical fingerprints associated with brain disorders to help formulate improved diagnostic classifications based on both brain and behavioral evaluations.

To validate our approach and address the vast heterogeneity of studies and measures reported, here we estimated and ranked effect sizes for regional brain volume abnormalities in individuals with schizophrenia using the same image analysis, quality assurance and statistical analysis methods across a large number of independently evaluated samples. We also explored effects of available demographics (age at onset, duration of illness, age, chlorpromazine dose equivalents, proportion of second-generation (atypical), first-generation (typical), both or no antipsychotic medication, and severity of positive and negative symptoms) and methodological variables (scanner field strength and FreeSurfer version) on the effect size estimates across studies. Based on the largest schizophrenia brain volume meta-analysis conducted to date, we predicted that individuals with schizophrenia would show smaller hippocampus, amygdala, thalamus, accumbens and intracranial volumes (ICVs), as well as larger pallidum and lateral ventricle volumes, compared with healthy controls.

MATERIALS AND METHODS

Study samples
Fifteen worldwide (see Supplementary Figure S1) cross-sectional study samples totaling 4568 participants—2028 individuals with schizophrenia and 2540 healthy controls—contributed to the collaborative analysis of subcortical brain volumes via the ENIGMA Schizophrenia Working Group (Supplementary Tables S3a and b). The sample-size-weighted mean age across samples was 31 (range: 23–42) years and for patients 34 (range: 22–43) years. The control and patient samples were on average 52% (range: 38–71%) and 69% male (range: 56–87%). The weighted mean age at onset and duration of illness across the patient groups were 23 (range: 20–29) and 10 (range: 0.8–20) years. The weighted mean total PANSS (Positive and Negative Syndrome Scale), SANS (Scale for the Assessment of Negative Symptoms) and SAPS (Scale for the Assessment of Positive Symptoms) total scores across the samples were 63 (range: 36–90), 24 (range: 15–33) and 18 (range: 8–41) years. For samples that recorded current antipsychotic type and dose, the percentage of patients on second-generation (atypical; 77%), first-generation (typical; 15%), both (3%) or none (5%) was determined and for 11 samples chlorpromazine dose equivalents were computed based on Woods (2005; www.scottwilliamwoods.com/files/Equivtext.doc). The size-weighted mean chlorpromazine dose equivalent across the samples was 436 (range: 276–704). Each study sample was collected with participants’ written informed consent approved by local Institutional Review Boards. No individual subject imaging or clinical data were shared among the ENIGMA institutions.

Image acquisition and processing
Left and right lateral ventricle, thalamus, caudate, putamen, pallidum, accumbens, hippocampus and amygdala volumes, as well as ICVs, were obtained with FreeSurfer (22–23) (http://surfer.nmr.mgh.harvard.edu) from high-resolution T1-weighted structural brain scans (Supplementary Tables S4 and S4a and o). Details on study type (single site or multisite), scanner vendor/strength/sequence, acquisition parameters and FreeSurfer versions used are provided in Supplementary Table S3b. For quality control, all regions of interest (ROIs) with a volume larger or < 1.5 times the interquartile range were identified and visually inspected by overlaying their segmentations on the subjects’ anatomical images. Only ROI data for which segmentation was judged accurate upon visual inspection were subjected to statistical analyses (see Supplementary Figure S2 for ROI volume histograms).

Statistical meta-analyses
Group differences for each ROI within each sample were examined using univariate linear regression analysis (R’s linear model function lm) predicting the mean of left and right subcortical volumes with group (patient, control). The main analysis (model 1) included sex, age and ICV as covariates. Secondary models excluded ICV (model 2) or ICV, sex and age (model 3; uncorrected means model) covariates. The analysis of ICV was performed with models 2 and 3. Analysis of multiscenter studies (FBIRN, MCIC) included binary dummy covariates for n –1 scanners. For each sample, Cohen’s d effect sizes for each ROI and model were computed based on the group contrast t-statistics, see Supplementary Information 1 for details. Explanatory analyses examined the effect sizes for left and right hemisphere ROIs separately. Analyses of individual subject data were performed by the site that contributed the sample, using code created within the ENIGMA collaboration. Everyone in the working group had access to statistical results from each site.

Moderator analyses
Meta-regression analyses examined associations between sample demographics (mean age at onset, duration of illness, age, chlorpromazine dose
RESULTS

Ranking group differences in terms of their effect sizes

Comparing with controls, individuals with schizophrenia showed significantly smaller hippocampus (mean difference from control mean: \(-4.10\%\)), amygdala \((-3.80\%)\), thalamus \((-2.74\%)\), accumens \((-3.69\%)\) and ICVs \((-0.30\%)\), as well as larger pallidum \(+2.28\%\) and lateral ventricle volumes \(+18.24\%\); see Figure 1 and Table 1). The biggest group effect control size was observed for smaller hippocampus volume \((d = -0.46, P = 4.85 \times 10^{-14})\), followed by larger lateral ventricle volume \((d = 0.37, P = 1.38 \times 10^{-8})\). Each of these brain structures, except intracranial \((P = 0.05, \text{two-tailed})\) and pallidum \((P = 0.02, \text{two-tailed})\), showed group differences at the conservative Bonferroni-corrected threshold of \(P < 0.0056\) (two-tailed). Group differences for putamen and caudate volumes were not detectably different from zero. Analysis without ICV as a covariate (model 2) did not substantially alter the effect sizes, or their ranking. Analyses of left and right hemisphere volumes showed similar findings as for their mean; removal of age and sex covariates (model 3) lowered all effect sizes (Supplementary Figures S1a and c). Heterogeneity of effect sizes, as measured by the \(I^2\) statistic, was moderately high to high for all regions (range: 68–87%). Effect sizes for each sample are provided in Supplementary Figure S3.

Moderator analyses

Moderator analyses use meta-regressions, which examine the effects of moderator variables on meta-analysis effect sizes using regression techniques. Our moderator analyses found that sample means for duration of illness and age were positively associated with putamen \((P = 0.002, P = 0.002, \text{respectively})\) and pallidum \((P = 0.0002; P = 0.002, \text{respectively})\) group contrast effect sizes. The sample proportions of medication-naïve patients were negatively associated with hippocampus group contrast effect sizes (Table 2, Supplementary Tables S2a and m and Supplementary Figure S4).

At an uncorrected statistical threshold \((P < 0.05)\), differences in sample proportions of males \((S2 \sim HV)\) were negatively associated with accumens \((P = 0.007)\) and amygdala \((P = 0.01)\) group contrast effect sizes, sample proportions of patients treated with second-generation antipsychotics were negatively associated with lateral ventricle group contrast effect sizes \((P = 0.04)\), sample means of current chlorpromazine dose equivalents were positively associated with lateral ventricle group contrast effect sizes \((P = 0.03)\), sample means for age of onset were negatively associated with hippocampus group contrast effect sizes \((P = 0.02)\), sample means for PANSS-negative symptom severity were negatively associated with lateral ventricle group contrast effect sizes \((P = 0.01)\) and scanner field strength \((1.5/3 T)\) was negatively associated with amygdala group contrast effect sizes \((P = 0.03)\).

There were no detectable effects of proportion of typical/both antipsychotics, or FreeSurfer version on any of the group contrast effect sizes (all \(P > 0.05\); Supplementary Tables S2a and m).

Power analyses

Our sample of 2028 individuals with schizophrenia and 2540 healthy controls provided 80% power to detect Cohen’s \(d\) effect sizes of 0.084 at \(P < 0.05\) (two-tailed) and 0.108 at the conservative Bonferroni-corrected threshold of \(P < 0.0056\) (two-tailed). Estimated sample sizes needed, in each group, to achieve 80% power to detect group differences at \(P < 0.05\) (one-tailed) across ROIs range from 25 to 15 450 (Table 1).

DISCUSSION

In the largest cooperative analysis to date of brain MRI scans from individuals with schizophrenia, we found that: (1) individuals with schizophrenia, compared with healthy controls, have significantly smaller hippocampus, amygdala, thalamus, accumens and ICVs, and significantly larger pallidum and lateral ventricle volumes; (2) the heterogeneity of effect sizes across samples was moderately high to high; (3) putamen and pallidum volume enlargements were associated with duration of illness and age and (4) hippocampal volume deficits were more severe in samples with a higher proportion of unmedicated patients.

The percent volume differences and effect sizes for ICV and subcortical volume abnormalities were small to moderate \((-4.10 \text{ to } 18.24\%)\), Cohen’s \(d = -0.46\) to 0.37\); patients and controls substantially overlapped in their distributions. The reported effect sizes provide important information for power estimates in schizophrenia imaging studies. The rank order and magnitude of effect sizes across regions here agrees with the largest retrospective meta-analysis performed to date,\(^{11}\) which examined 38 brain structures, analyzed using a variety of different methods, across 382 samples (317 studies) combining data from over 18 000 subjects. The biggest effect size was observed for smaller hippocampus volumes \((d = -0.46)\) followed by larger lateral ventricle volumes \((d = 0.37)\) in patients versus controls. Despite FreeSurfer’s relatively crude measure of intracranial brain volume, based on registration scaling parameters, our findings agree with other reports of smaller average intracranial brain volumes in individuals with schizophrenia versus controls.\(^{5,11}\) This is consistent with a role for disturbed brain development in the disorder. The lack of detectable differences in caudate and putamen volumes among individuals with schizophrenia on antipsychotic medications also corroborates the findings by Hajima et al.\(^{11}\) who

© 2015 Macmillan Publishers Limited

Figure 1. Cohen’s \(d\) effect sizes ± s.e. for regional brain volume differences between Individuals with schizophrenia and healthy controls. Effect sizes for all subcortical volumes depicted were corrected for sex, age and intracranial volume (ICV). The effect size for ICV was corrected for sex and age. The number of independent data points \((N_{52} \text{ and } N_{150})\) for each region are listed in Table 1.
observed smaller caudate volumes only in medication-naive individuals with schizophrenia compared with controls.

The effect size estimates based on analyses excluding ICV (model 2) as compared to including ICV (model 1) showed the exact same pattern (Supplementary Tables S1a and c). As expected from the lower ICV in patients compared with controls, the negative effect sizes were slightly more negative and the positive effect sizes were slightly less positive. All effect sizes significant in model 1 remained significant in model 2. Subcortical brain abnormalities are therefore largely independent of intracranial volume. Removing age and sex from the analysis rendered group contrasts for intracranial volume nonsignificant and lowered subcortical volume effect sizes. This is not surprising: removing covariates that explain variance increases error variance, and reduces effect size.

Despite using similar imaging, quality assurance and analysis methods, effect size heterogeneity across the samples was moderately high to high for all regions ($r^2$ range: 60–87%). Indeed, the heterogeneity is even larger than that observed in the largest retrospective meta-analysis.13 Although unexpected, this finding may suggest that prospective meta-analyses, compared with retrospective meta-analyses, show more true variation in effect sizes owing to unselective reporting; the latter may show more restricted variance owing to publication bias.

We found significant positive associations between duration of illness as well as age and putamen and pallidum volume exacerbations in schizophrenia. We also found that hippocampal volume deficits showed a significant negative association with the proportion of unmedicated patients. Meta-regression analyses must be interpreted cautiously, owing to possible confounds (e.g., Simpson’s paradox26), but can be useful for hypothesis generation. The positive association between duration of illness and the volumes of the putamen and pallidum may reflect, in part, the cumulative effects of antipsychotic medication treatment on basal ganglia volumes; the association for caudate volume was also positive, although not significant. Several longitudinal studies report that antipsychotic treatments normalize caudate volume deficits observed in medication-naive patients11 and increase putamen volumes.27–32 Few studies report medication effects in the pallidum. Caudate, putamen and pallidum volume–ICV ratios may predict risperidone treatment effects in individuals with schizophrenia.33 One retrospective meta-analysis suggests that cumulative exposure to antipsychotic treatments is associated with gray matter volume loss,34 but the field would benefit from a prospective meta-analysis of longitudinal studies examining how antipsychotic medications affect brain morphology over time, especially because many studies only report data from a select set of regions.

As duration of illness is highly correlated with age ($r_{ill} = 0.91$, $P < 0.001$), we cannot exclude the possibility of disease-related age effects on these regions. The latter interpretation is consistent with independently replicated findings of larger pallidum volumes in unmedicated, non-ill relatives of individuals with schizophrenia. Hence, larger pallidum volumes may be associated with familial (possibly genetic) liability5,36 (but see Honen et al.,37 for a conflicting finding, perhaps reflecting confounding factors). Longitudinal

---

### Table 1. Cohen’s $d$ effect sizes by region

<table>
<thead>
<tr>
<th>Region</th>
<th>Cohen’s $d$</th>
<th>$P$-value</th>
<th>95% CI</th>
<th>% Difference</th>
<th>N80</th>
<th>$r^2$</th>
<th>N25</th>
<th>NHV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hippocampus</td>
<td>$-0.46$</td>
<td>$4.85 \times 10^{-14}$</td>
<td>$-0.58$ to $-0.34$</td>
<td>$-4.10$</td>
<td>25</td>
<td>71</td>
<td>2021</td>
<td>2531</td>
</tr>
<tr>
<td>Amygdala</td>
<td>$-0.31$</td>
<td>$3.59 \times 10^{-7}$</td>
<td>$-0.43$ to $-0.19$</td>
<td>$-3.80$</td>
<td>60</td>
<td>71</td>
<td>2024</td>
<td>2535</td>
</tr>
<tr>
<td>Thalamus</td>
<td>$-0.31$</td>
<td>$1.31 \times 10^{-6}$</td>
<td>$-0.44$ to $-0.18$</td>
<td>$-2.74$</td>
<td>60</td>
<td>74</td>
<td>2022</td>
<td>2533</td>
</tr>
<tr>
<td>Accumbers</td>
<td>$-0.25$</td>
<td>$1.54 \times 10^{-5}$</td>
<td>$-0.36$ to $-0.14$</td>
<td>$-3.69$</td>
<td>95</td>
<td>68</td>
<td>2018</td>
<td>2535</td>
</tr>
<tr>
<td>ICV</td>
<td>$0.12$</td>
<td>$0.05$</td>
<td>$-0.24$ to $0.00$</td>
<td>$-0.30$</td>
<td>425</td>
<td>73</td>
<td>2026</td>
<td>2539</td>
</tr>
<tr>
<td>Caudate</td>
<td>$0.02$</td>
<td>$0.73$</td>
<td>$-0.12$ to $0.16$</td>
<td>$-0.20$</td>
<td>15</td>
<td>450</td>
<td>79</td>
<td>2024</td>
</tr>
<tr>
<td>Putamen</td>
<td>$0.08$</td>
<td>$0.36$</td>
<td>$-0.09$ to $0.25$</td>
<td>$0.20$</td>
<td>962</td>
<td>86</td>
<td>2023</td>
<td>2536</td>
</tr>
<tr>
<td>Pallidum</td>
<td>$0.21$</td>
<td>$0.02$</td>
<td>$0.04$ to $0.39$</td>
<td>$2.28$</td>
<td>136</td>
<td>87</td>
<td>2015</td>
<td>2538</td>
</tr>
<tr>
<td>Lateral ventricle</td>
<td>$0.37$</td>
<td>$1.38 \times 10^{-9}$</td>
<td>$0.25$ to $0.49$</td>
<td>$18.24$</td>
<td>41</td>
<td>71</td>
<td>2028</td>
<td>2539</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval; HV, healthy volunteer; $r^2$, heterogeneity index; ICV, intracranial volume; N80, number of subjects needed in each group for 80% power to detect significant group differences ($P < 0.05$, one-tailed); N25 and NHV, the number of subjects with schizophrenia and healthy volunteers included in the analysis, respectively. Group contrast (Sz – HV) effect sizes for mean (left+right)/2 volumes controlling for age, sex and ICV. Effect size for ICV controlling for age and sex.52 % Difference = mean weighted percent difference in volume between patients and controls ((Sz – HV)/HV) × 100.

### Table 2. Moderator (meta-regression) analysis $P$-values

<table>
<thead>
<tr>
<th>Duration of illness</th>
<th>Age</th>
<th>Proportion of unmedicated patients</th>
<th>Difference (Sz – HV), proportion of males</th>
<th>Proportion of second-generation antipsychotics</th>
<th>CPZ dose equivalents</th>
<th>Age of onset</th>
<th>PANSS negative</th>
<th>Scanner field strength</th>
<th>FreeSurfer version</th>
</tr>
</thead>
<tbody>
<tr>
<td>Putamen</td>
<td>0.002</td>
<td>0.001</td>
<td>0.49</td>
<td>0.11</td>
<td>0.48</td>
<td>0.53</td>
<td>0.34</td>
<td>0.24</td>
<td>0.23</td>
</tr>
<tr>
<td>Pallidum</td>
<td>0.0002</td>
<td>0.002</td>
<td>0.58</td>
<td>0.69</td>
<td>0.52</td>
<td>0.68</td>
<td>0.15</td>
<td>0.96</td>
<td>0.82</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>0.57</td>
<td>0.11</td>
<td>0.003</td>
<td>0.22</td>
<td>0.52</td>
<td>0.20</td>
<td>0.02</td>
<td>0.49</td>
<td>0.54</td>
</tr>
<tr>
<td>Lat. ventricle</td>
<td>0.30</td>
<td>0.16</td>
<td>0.28</td>
<td>0.65</td>
<td>0.04</td>
<td>0.03</td>
<td>0.28</td>
<td>0.01</td>
<td>0.43</td>
</tr>
<tr>
<td>Thalamus</td>
<td>0.84</td>
<td>0.32</td>
<td>0.43</td>
<td>0.96</td>
<td>0.81</td>
<td>0.08</td>
<td>0.09</td>
<td>0.15</td>
<td>0.72</td>
</tr>
<tr>
<td>Caudate</td>
<td>0.22</td>
<td>0.22</td>
<td>0.99</td>
<td>0.69</td>
<td>0.19</td>
<td>0.46</td>
<td>0.73</td>
<td>0.58</td>
<td>0.34</td>
</tr>
<tr>
<td>Amygdala</td>
<td>0.43</td>
<td>0.26</td>
<td>0.35</td>
<td>0.01</td>
<td>0.66</td>
<td>0.26</td>
<td>0.78</td>
<td>0.35</td>
<td>0.04</td>
</tr>
<tr>
<td>Accumbers</td>
<td>0.15</td>
<td>0.13</td>
<td>0.40</td>
<td>0.007</td>
<td>0.30</td>
<td>0.21</td>
<td>0.66</td>
<td>0.073</td>
<td>0.17</td>
</tr>
<tr>
<td>ICV</td>
<td>0.78</td>
<td>0.89</td>
<td>0.43</td>
<td>0.70</td>
<td>0.85</td>
<td>0.06</td>
<td>0.40</td>
<td>0.087</td>
<td>0.19</td>
</tr>
</tbody>
</table>

**Abbreviations:** CPZ, chlorpromazine; HV, healthy volunteers; ICV, intracranial volume; Sz, schizophrenia. Italic $P$-values are significant at the Bonferroni-corrected threshold of $P < 0.0056$. Bolded $P$-values are significant at a nominal $P$-value of $P < 0.05$ (two-tailed).
studies of clinically and/or genetically at-risk individuals are needed to examine whether subcortical abnormalities, such as larger pallidum volumes, reflect abnormal developmental trajectories, in the absence of confounding factors (e.g., medications), as suggested by abnormal associations of subcortical volumes with age in adolescents at familial risk for schizophrenia.38

The finding that a larger proportion of unmedicated patients was associated with larger hippocampal volume deficits is surprising and warrants replication. This finding suggests that untreated psychosis may be associated with more severe hippocampus volume deficits and perhaps that hippocampal volume deficits may be partially ameliorated by (atypical) antipsychotic medications. This interpretation is supported by a longitudinal study finding that schizophrenia patients with cumulative higher dose of atypical antipsychotics showed less decrease or even small increases in hippocampus volumes over time39 and findings of neurogenic effects of atypical but not typical antipsychotics in the hippocampus subgranular zone.40 Notably, the 11 samples included in this meta-regression were predominantly treated with atypical antipsychotics (sample-size-weighted mean = 77%). Our exploratory findings include smaller accumbens (P = 0.007) and amygdala (P = 0.01) deficits among samples with larger proportions of males in the schizophrenia compared with the control sample. Most neuroimaging studies equate sex distributions between comparison groups and our findings indicate that this may be particularly important when examining accumbens and amygdala volumes. We also found that sample proportions of patients treated with second-generation antipsychotics were associated with smaller lateral ventricle volume enlargement (P = 0.04); a finding perhaps consistent with observations of smaller decreases in brain volumes in patients taking second-compared with first-generation antipsychotic medications.41 In contrast, current chlorpromazine dose equivalents were positively associated with lateral ventricle volume exacerbations (P = 0.03); the nature of this association remains to be determined. Most unexpected, and in contrast to early findings,42 higher severity of negative symptoms was associated with smaller lateral ventricle volumes (P = 0.01). However, we believe that associations between symptom severity and subcortical volumes are best studied within site, followed by between site meta-analyses of the observed within-site beta-weights in particular because no reliability for symptom ratings was established between sites. Such analyses are currently under development for cortical thickness and possible findings for the subcortical volumes will be reported in the planned manuscript. Also unexpected, given prior findings showing opposite effects, is that higher mean age of onset was associated with larger hippocampal volume deficits. This finding may be consistent with larger hippocampus volume deficits in patients with a longer duration of untreated psychosis,43 an interpretation consistent with this study’s finding that hippocampal deficits scale with the proportion of unmedicated patients. The only methodological effect observed was that of larger amygdala deficits at higher scanner field strength (3 versus 1.5 T). Brain volumes in traditional studies are more reliably at 3 versus 1.5 T, perhaps due to reduced partial volume effects associated with smaller voxels used at 3T.44 Reliabilities for amygdala volumes at 1.5 and 3 T are comparable when the same voxel size is used.45

Strengths of this study include sample sizes of over 2018 patients and 2533 controls for each brain region (Table 1). For measures other than intracranial and hippocampal volumes, this study constitutes the largest meta-analysis of subcortical brain volumes in schizophrenia to date. A second strength is the use of similar image analysis, quality assurance and statistical analysis methods across all brain regions from all 15 contributing studies. Individual studies can maximize their statistical power by restricting analyses to a smaller number of a priori regions of interest, but in prospective meta-analyses participating sites are free to include brain measures that would otherwise remain unexplored.

A similar strategy to the one used in this study has been used in an international mega-analysis of structural imaging in bipolar disorder46 as well as in parallel ENIGMA—Bipolar Disorder (BD) and Major Depressive Disorder Working Group studies, which found significantly smaller hippocampus, amygdala and thalamus, and significantly larger lateral ventricle volumes in bipolar disorder47 and smaller hippocampus volumes in major depressive disorder compared with controls with the latter effect mainly present in individuals with recurrent major depressive disorder and/or with an illness onset before age 22 years.48 Our prospective meta-analyses strategy generates highly significant findings and may be particularly useful in areas where study samples are traditionally small or for which no comprehensive regional assessment of brain morphology has been pursued—for example, high-risk, medication-naive first-episode, longitudinal medication studies, and comparisons across diagnostic boundaries.

This study has some weaknesses. We used the same image analysis package across all samples (FreeSurfer), but a recent study showed effects of FreeSurfer version, workstation vendor and operating system version on brain volume and cortical thickness estimates.49 Here, however, FreeSurfer version did not predict effect sizes across studies for any of the regions examined. Second, the overall sample included a higher proportion of males in the patient (69%) compared with the control group (52%). It is however unlikely that this discrepancy affects our findings because (a) they replicate those of Hajjma et al.50 who included only studies matched for sex distribution, and (b) meta-regression predicting effect sizes with group difference in the proportion of males only showed a significant effect for the accumbens and the amygdala, for which a higher proportion of males in the schizophrenia compared with the control group was negatively associated with group contrast effect sizes (P = 0.007 and P = 0.01, respectively; Table 2 and Supplementary Tables S2a and m). Third, our analysis only examined cross-sectional studies of individuals with schizophrenia and healthy controls and only examined subcortical and intracranial brain volumes. Fourth, apart from disease-related biological factors, numerous confounding environmental factors can influence the volume of brain structures, including fetal hypoxia,50 nutritional and hydration status,51–53 exercise,54 medications,11 smoking,55 cannabis use,41 social isolation,56 and the stress associated with severe mental illness.57 Parsing the contributions of such factors is an ongoing effort within as well as outside the consortium. This is, however, a first validation study for which significant efforts were put forward to grow the consortium and develop a first robust analyses allowing for validation of the approach. Plans for additional analyses of patients’ relatives, relationship to more detailed clinical symptoms and the study of additional brain measures (e.g., volume and thickness of cortical ROIs) are under development.

In conclusion, this study shows a robust pattern of subcortical brain abnormalities, suggests that that larger putamen and pallidum volumes may be associated with duration of illness in schizophrenia and suggests that treatment with predominantly second-generation (atypical) antipsychotics may ameliorate hippocampal volume deficits. The consistency between the reported prospective meta-analysis findings and those from traditional retrospective meta-analyses validate the prospective meta-analysis approach. We are in the process applying similar methods to cortical thickness and surface, as well as less well-studied subcortical shape measures. For a review of ongoing efforts and to join the collaborative see http://enigma.ini.usc.edu.
ACKNOWLEDGMENTS

For grant support and acknowledgments see Supplementary Information 2.

AUTHOR CONTRIBUTIONS

Protocol design, quality testing and meta-analysis: DPH, TGMvE, JMR. Data collection, processing, analysis and funding: TGMvE, DPH, JMR, DCG, GDP, OAA, IA, LIW, UKH, AMD, CBH, OG, BK, DZ, GD, SK, CM, DWM, DMC, AC, MWJM, LK, LDh, DJV, TDS, DHW, RCG, SLP, DHA, BM, AP, FM, SE, EW, JH, VDC, HJB, SRS, JMS, NEMvH, HEHP, RAO, RSK, RR-S, BC-F, LW, KIA, EGI, RD, BC, HW, AMM, SML, PMT, JAT; manuscript preparation: TGMvE, JAT and PMT. All authors contributed edits and approved the contents of the manuscript.

REFERENCES


47 Hibar DP Robust subcortical volumetric reductions in bipolar disorder: findings from the ENIGMA bipolar disorder working group including 1,745 cases and 2,613 controls. Proc Natl Acad Sci USA (submitted).
48 Schmaal L Subcortical brain volume abnormalities in major depressive disorder: prospective meta-analytic findings from the ENIGMA Major Depressive Disorder Working Group including 1,808 cases and 7,223 controls. Proc Natl Acad Sci USA (submitted).

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)